Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma

Abstract Bortezomib, lenalidomide, and dexamethasone (VRD), and bortezomib, doxorubicin, and dexamethasone (PAD), are commonly used in induction regimens for patients with newly diagnosed multiple myeloma (NDMM) in China. This real-world study enrolled 390 patients, 195 receiving VRD and 195 receivi...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Dong Liang, Shenrui Bai, Demei Feng, Guanjun Chen, Yang Liang, Hua Wang
Format: Article
Language:English
Published: BMC 2024-09-01
Subjects:
Bortezomib
Lenalidomide
And dexamethasone
Doxorubicin
Online Access:https://doi.org/10.1186/s12885-024-12880-9

Internet

https://doi.org/10.1186/s12885-024-12880-9

Similar Items